Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial ...

Colorectal cancer remains the third most commonly diagnosed cancer in both men and women in the United States, with approximately 153,000 new cases expected this year alone. While overall rates have ...

Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to ...

The surgical outcomes of colon cancer vary with its anatomical location. Neoadjuvant chemotherapy can aid in improving the postsurgical outcomes of both right and left colon cancer, decreasing the ...

Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a phase I unit. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Colorectal cancer is the fourth-most-common cancer in the U.S. and the second deadliest. One in 5 patients is diagnosed with metastatic disease, meaning the colorectal cancer has spread beyond the ...

Researchers have developed and internally validated a simple score using clinical factors that can help estimate the likelihood of advanced colorectal neoplasia in adults younger than age 45 years.

Bottom Line: A pre-existing diagnosis of dementia was associated with increased risk of death for older patients with advanced colon cancer; however, some of the effects of dementia on survival could ...

New research recently presented by Dr. Timothy Cannon in a poster session at the 2025 American Society of Clinical Oncology conference is seeking to understand whether ultramarathon running is a risk ...